Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

DNDi, Astellas partner on new drug discovery research for treatment of NTDs

Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.

12 Jun 2012

CRT, BioInvent partner to identify new therapeutic antibodies in oncology

BioInvent International AB and Cancer Research Technology Ltd (CRT), the commercial arm of Cancer Research UK, announced today that they have entered a collaboration with Queen Mary, University of London, to identify new therapeutic antibodies in oncology.

12 Jun 2012

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.

From BD (Becton, Dickinson and Company) 11 Jun 2012

Cambridge facility to become worldwide hub for SAFC's chiral service

Sigma-Aldrich Corporation today announced that its custom manufacturing and services business unit, SAFC, will consolidate its global chiral chromatography screening and small scale purification operations and locate them at its Pharmorphix Solid State Research Laboratories in Cambridge, UK, to support its new integrated chiral chemistry offer.

11 Jun 2012

ADAM28 inhibits VWF-mediated cancer cell apoptosis and enhances lung metastases

ADAM28, a metalloproteinase belonging to the ADAM gene family, cleaves the von Willebrand factor (VWF) and inhibits VWF-mediated cancer cell apoptosis, thereby enhancing lung metastases, so inhibiting its expression gives a substantial reduction in lung metastases, according to a study published June 8 in the Journal of The National Cancer Institute.

11 Jun 2012

Scientists create cancer model built in the fruit fly Drosophila

Researchers from Mount Sinai School of Medicine developed a cancer model built in the fruit fly Drosophila, then used it to create a whole new approach to the discovery of cancer treatments. The result is an investigational compound AD80 that precisely targets multiple cancer genes.

8 Jun 2012

CDI introduces MyCell Services

Cellular Dynamics International, Inc. (CDI), the world's largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell Services.

7 Jun 2012

Investigational diabetes drug appears to improve insulin sensitivity without side effects

Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.

5 Jun 2012

ShangPharma celebrates 10th anniversary of partnership with Lilly

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today celebrated the 10th anniversary of its partnership with Eli Lilly and Company.

4 Jun 2012

Lilly launches clinical trial mobile app for oncology healthcare professionals

Today, Eli Lilly and Company launched a searchable clinical trial mobile application for oncology healthcare professionals.

2 Jun 2012

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Results published in Blood, the official journal of the American Society of Hematology, confirm that inhibition of the IRE1α-XBP1 pathway impacts the survival of myeloma cells, suggesting a promising therapeutic option in multiple myeloma.

2 Jun 2012

Breakthrough in nanotechnology could make laboratory tests more sensitive

A laboratory test used to detect disease and perform biological research could be made more than 3 million times more sensitive, according to researchers who combined standard biological tools with a breakthrough in nanotechnology.

2 Jun 2012

Affymetrix, Leica Microsystems enter worldwide collaboration on RNA ISH analysis

Affymetrix, Inc. and Leica Microsystems are pleased to announce a world-wide collaboration that automates Affymetrix' QuantiGene ViewRNA ISH Tissue Assay on the Leica BOND RX staining platform for research applications.

1 Jun 2012

New method can solve 3-D structures of integral membrane proteins

A new method for rapidly solving the three-dimensional structures of a special group of proteins, known as integral membrane proteins, may speed drug discovery by providing scientists with precise targets for new therapies, according to a paper published May 20 in Nature Methods.

31 May 2012

YCC, SCRI and SCH partner to advance cancer research

Sarah Cannon Research Institute (SCRI) today announced the finalization of an agreement to collaborate scientifically with Yale Cancer Center (YCC) and Smilow Cancer Hospital at Yale-New Haven (SCH) to advance cancer research.

31 May 2012

Bristol-Myers Squibb forms International Immuno-Oncology Network

Bristol-Myers Squibb Company today announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology. Immuno-oncology focuses on the potential of harnessing the intelligence of the body's own immune system to fight cancer.

30 May 2012

Lung in Oncology models for drug discovery launched by PRECOS

Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, has launched its Lung In ONcology model atlas (LION).

29 May 2012

Fluxion Biosciences announces launch of Discovery Services business

Fluxion Biosciences, a privately held drug discovery tools and services company, announced today that it is launching a Discovery Services business to support growing demand for assay support on Fluxion's unique cell analysis platforms.

From Fluxion Biosciences 29 May 2012

Ensemble, Genentech enter macrocyclic drug discovery collaboration

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced the initiation of a drug discovery collaboration with Genentech, a member of the Roche Group, to discover macrocyclic drug candidates against targets specified by Genentech.

29 May 2012

Single test developed that detects all known strains of H5N1

The close collaboration between scientists from the Experimental Therapeutics Centre (ETC) under the Agency for Science and Technology Research (A*STAR) and clinicians from Tan Tock Seng Hospital (TTSH) has enabled the successful development of the most comprehensive and rapid H5N1 bird flu test kit available to date.

29 May 2012